Biodexa Pharmaceuticals PLC (BDRX) Business News Nov. 24, 2025, 13:30 UTC Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP Full text
Register to leave comments News bot Nov. 24, 2025, 1:42 p.m. 📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (78%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical